These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 25179327)

  • 1. Predictors of use of infection control precautions for multiresistant gram-negative bacilli in Australian hospitals: analysis of a national survey.
    Rogers BA; Havers SM; Harris-Brown TM; Paterson DL
    Am J Infect Control; 2014 Sep; 42(9):963-9. PubMed ID: 25179327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk associated with a systematic search of extended-spectrum β-lactamase-producing Enterobacteriaceae.
    Prinapori R; Guinaud J; Khalil A; Lecuyer H; Gendrel D; Lortholary O; Nassif X; Viscoli C; Zahar JR
    Am J Infect Control; 2013 Mar; 41(3):259-60. PubMed ID: 23062579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bloodstream infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care hospital in New Zealand: risk factors and outcomes.
    Freeman JT; McBride SJ; Nisbet MS; Gamble GD; Williamson DA; Taylor SL; Holland DJ
    Int J Infect Dis; 2012 May; 16(5):e371-4. PubMed ID: 22401750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rate of transmission of extended-spectrum beta-lactamase-producing enterobacteriaceae without contact isolation.
    Tschudin-Sutter S; Frei R; Dangel M; Stranden A; Widmer AF
    Clin Infect Dis; 2012 Dec; 55(11):1505-11. PubMed ID: 22955436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contact precautions in single-bed or multiple-bed rooms for patients with extended-spectrum β-lactamase-producing Enterobacteriaceae in Dutch hospitals: a cluster-randomised, crossover, non-inferiority study.
    Kluytmans-van den Bergh MFQ; Bruijning-Verhagen PCJ; Vandenbroucke-Grauls CMJE; de Brauwer EIGB; Buiting AGM; Diederen BM; van Elzakker EPM; Friedrich AW; Hopman J; Al Naiemi N; Rossen JWA; Ruijs GJHM; Savelkoul PHM; Verhulst C; Vos MC; Voss A; Bonten MJM; Kluytmans JAJW;
    Lancet Infect Dis; 2019 Oct; 19(10):1069-1079. PubMed ID: 31451419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surveillance of extended-spectrum beta-lactamase-producing bacteria and routine use of contact isolation: experience from a three-year period.
    Kola A; Holst M; Chaberny IF; Ziesing S; Suerbaum S; Gastmeier P
    J Hosp Infect; 2007 May; 66(1):46-51. PubMed ID: 17350720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Extended-spectrum of beta-lactamases (ESBL): yesterday ESBL: and today ESBL, carbapenemase-producing and multiresistant bacteria].
    Ghebremedhin B
    Dtsch Med Wochenschr; 2012 Dec; 137(50):2657-62. PubMed ID: 23225190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disparity in infection control practices for multidrug-resistant Enterobacteriaceae.
    Lowe C; Katz K; McGeer A; Muller MP;
    Am J Infect Control; 2012 Nov; 40(9):836-9. PubMed ID: 22361360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of multiresistant Gram-negative organisms in a surgical hospital in Ho Chi Minh City, Vietnam.
    Jones SL; Nguyen VK; Nguyen TM; Athan E
    Trop Med Int Health; 2006 Nov; 11(11):1725-30. PubMed ID: 17054753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variation in definitions and isolation procedures for multidrug-resistant Gram-negative bacteria: a survey of the Society for Healthcare Epidemiology of America Research Network.
    Drees M; Pineles L; Harris AD; Morgan DJ
    Infect Control Hosp Epidemiol; 2014 Apr; 35(4):362-6. PubMed ID: 24602940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The outcome of treating ESBL infections with carbapenems vs. non carbapenem antimicrobials.
    Trivedi M; Patel V; Soman R; Rodriguez C; Singhal T
    J Assoc Physicians India; 2012 Aug; 60():28-30. PubMed ID: 23405518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The current state of multidrug-resistant gram-negative bacilli in North America.
    Nicasio AM; Kuti JL; Nicolau DP
    Pharmacotherapy; 2008 Feb; 28(2):235-49. PubMed ID: 18225969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Mar; 58(10):256-60. PubMed ID: 19300408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vital Signs: Containment of Novel Multidrug-Resistant Organisms and Resistance Mechanisms - United States, 2006-2017.
    Woodworth KR; Walters MS; Weiner LM; Edwards J; Brown AC; Huang JY; Malik S; Slayton RB; Paul P; Capers C; Kainer MA; Wilde N; Shugart A; Mahon G; Kallen AJ; Patel J; McDonald LC; Srinivasan A; Craig M; Cardo DM
    MMWR Morb Mortal Wkly Rep; 2018 Apr; 67(13):396-401. PubMed ID: 29621209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duration of colonization by extended-spectrum β-lactamase-producing Enterobacteriaceae after hospital discharge.
    Birgand G; Armand-Lefevre L; Lolom I; Ruppe E; Andremont A; Lucet JC
    Am J Infect Control; 2013 May; 41(5):443-7. PubMed ID: 22998785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of extended spectrum beta-lactamase among multidrug resistant gram-negative isolates from a general hospital in Saudi Arabia.
    Kader AA; Kumar AK
    Saudi Med J; 2004 May; 25(5):570-4. PubMed ID: 15138522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting Antibiotic Resistance in Urinary Tract Infection Patients with Prior Urine Cultures.
    Dickstein Y; Geffen Y; Andreassen S; Leibovici L; Paul M
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4717-21. PubMed ID: 27216064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the clinical significance of production of extended-spectrum beta-lactamases (ESBL) by Enterobacteriaceae.
    Henshke-Bar-Meir R; Yinnon AM; Rudensky B; Attias D; Schlesinger Y; Raveh D
    Infection; 2006 Apr; 34(2):66-74. PubMed ID: 16703295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The emerging threat from carbapenem-resistant enterobacteriaceae.
    Landry J; Hurst H
    Nurs Womens Health; 2013 Dec; 17(6):519-24. PubMed ID: 24589052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carbapenem-resistant enterobacteriaceae: an emerging problem in children.
    Logan LK
    Clin Infect Dis; 2012 Sep; 55(6):852-9. PubMed ID: 22700827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.